HomeVideosTreatmentProjectsFriends
Site Wide RSS Feed


Home
STEM CELL TREATMENTS AVAILABLE TODAY
 
QUICK FIND ARTICLES ON YOUR MEDICAL CONDITION OR AREA OF INTEREST
 

The Don Margolis Blog

Featuring the most comprehensive collection of "disease specific" stem cell treatment articles in the world. We provide the most current, factual and comprehensive information on available stem cell treatments today for your specific medical condition.

NEED STEM CELL INFO RELEVANT TO YOU?
Go to the MEDICAL CONDITION column to the left to search our extensive database of stem cell treatment articles.

----------

I'M READY FOR TREATMENT!
  • Go to TREATMENT INFORMATION and fill out the medical form to receive personalized information on stem cell treatments for your specific condition.
  • Watch the video below for immediate information.


I WANT THE LATEST STEM CELL TREATMENT INFORMATION!
  • Go to NEWSLETTER SIGN UP to receive regular updates on stem cell treatments for multiple diseases.

WHO IS DON MARGOLIS?

----------

Still can't find what you're looking for?
For more specific searches, use the search bar at the top right or contact a patient coordinator at: 214-556-6377

Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
GUWAHATI: A 61-year-old heart patient from Silchar successfully underwent a stem cell operation at a private hospital here after stem cells extracted from his bone marrow were used to regenerate worn-out cells in his heart. Hospital authorities said the procedure was performed in the northeast for the first time.




http://www.vectorfree.com/media/vectors/cardiac-vector.jpg

The patient, Gopal Krishna Goswami, underwent the procedure on November 21. Diabetic Goswami's heart was functioning at 29% of its capacity due to degeneration of cells. In medical parlance, he was suffering from 'chronic poorly compensated heart failure'.

 

"Stem cell therapy provides hope in cases which are beyond the reach of conventional treatment. Goswami was suffering from a weak heart. His heart had almost stopped pumping blood and he couldn't even walk a few steps," Goswami's surgeon Bikash Rai Das said.

The bone marrow was extracted from his hip bone, said the doctor. It was then sent to a facility in Mumbai for extraction of stem cells. The procedure was carried out in collaboration with the Mumbai-based stem cell bank and therapy centre. With stem cell therapy becoming increasingly popular, its introduction in the region is expected to usher in positive changes in the northeast's health sector.

Goswami will have to go through five sittings of stem cell infusion and his next sitting will be within 45 days, his doctor said. A therapy of this sort requires screening by a government-approved ethics committee. The candidate's medical history is probed before the go-ahead is given. Screening can take anything between seven to 10 days.

Stem cell therapy provides hope in cases which are beyond the reach of conventional treatment.
Posted: 12/4/2014 10:27:42 AM by Don Margolis | with 0 comments


Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
NIH scientists find that restocking new cells in the brain’s center for smell maintains crucial circuitry.

For decades, scientists thought that neurons in the brain were born only during the early development period and could not be replenished.  More recently, however, they discovered cells with the ability to divide and turn into new neurons in specific brain regions. The function of these neuroprogenitor cells remains an intense area of research. Scientists at the National Institutes of Health (NIH) report that newly formed brain cells in the mouse olfactory system — the area that processes smells — play a critical role in maintaining proper connections. The results were published in the October 8 issue of the Journal of Neuroscience. 
 
“This is a surprising new role for brain stem cells and changes the way we view them,” said Leonardo Belluscio, Ph.D., a scientist at NIH’s National Institute of Neurological Disorders and Stroke (NINDS) and lead author of the study.
 
The olfactory bulb is located in the front of the brain and receives information directly from the nose about odors in the environment. Neurons in the olfactory bulb sort that information and relay the signals to the rest of the brain, at which point we become aware of the smells we are experiencing. Olfactory loss is often an early symptom in a variety of neurological disorders, including Alzheimer’s and Parkinson’s diseases.

In a process known as neurogenesis, adult-born neuroprogenitor cells are generated in the subventricular zone deep in the brain and migrate to the olfactory bulb where they assume their final positions. Once in place, they form connections with existing cells and are incorporated into the circuitry.
 
Dr. Belluscio, who studies the olfactory system, teamed up with Heather Cameron, Ph.D., a neurogenesis researcher at the NIH’s National Institute of Mental Health, to better understand how the continuous addition of new neurons influences the circuit organization of the olfactory bulb. Using two types of specially engineered mice, they were able to specifically target and eliminate the stem cells that give rise to these new neurons in adults, while leaving other olfactory bulb cells intact. This level of specificity had not been achieved previously.    
 
In the first set of mouse experiments, Dr. Belluscio’s team first disrupted the organization of olfactory bulb circuits by temporarily plugging a nostril in the animals, to block olfactory sensory information from entering the brain. His lab previously showed that this form of sensory deprivation causes certain projections within the olfactory bulb to dramatically spread out and lose the precise pattern of connections that show under normal conditions. These studies also showed that this widespread disrupted circuitry could re-organize itself and restore its original precision once the sensory deprivation was reversed.
 
However, in the current study, Dr. Belluscio’s lab reveals that once the nose is unblocked, if new neurons are prevented from forming and entering the olfactory bulb, the circuits remain in disarray. “We found that without the introduction of the new neurons, the system could not recover from its disrupted state,” said Dr. Belluscio.
 
To further explore this idea, his team also eliminated the formation of adult-born neurons in mice that did not experience sensory deprivation. They found that the olfactory bulb organization began to break down, resembling the pattern seen in animals blocked from receiving sensory information from the nose. And they observed a relationship between the extent of stem cell loss and amount of circuitry disruption, indicating that a greater loss of stem cells led to a larger degree of disorganization in the olfactory bulb.
 
According to Dr. Belluscio, it is generally assumed that the circuits of the adult brain are quite stable and that introducing new neurons alters the existing circuitry, causing it to re-organize. “However, in this case, the circuitry appears to be inherently unstable requiring a constant supply of new neurons not only to recover its organization following disruption but also to maintain or stabilize its mature structure. It’s actually quite amazing that despite the continuous replacement of cells within this olfactory bulb circuit, under normal circumstances its organization does not change,” he said.
 
Dr. Belluscio and his colleagues speculate that new neurons in the olfactory bulb may be important to maintain or accommodate the activity-dependent changes in the system, which could help animals adapt to a constantly varying environment.
 
“It’s very exciting to find that new neurons affect the precise connections between neurons in the olfactory bulb. Because new neurons throughout the brain share many features, it seems likely that neurogenesis in other regions, such as the hippocampus, which is involved in memory, also produce similar changes in connectivity,” said Dr. Cameron.
 
The underlying basis of the connection between neurological disease and changes in the olfactory system is also unknown but may come from a better understanding of how the sense of smell works. “This is an exciting area of science,” said Dr. Belluscio, “I believe the olfactory system is very sensitive to changes in neural activity and given its connection to other brain regions, it could lend insight into the relationship between olfactory loss and many brain disorders.”
 
This work was supported by the NIH Intramural Program.
 
For more information about brain research, please visit http://www.ninds.nih.gov
 
NINDS is the nation’s leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. 
 
About the National Institute of Mental Health (NIMH): The mission of the NIMH is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery and cure. For more information, visit http://www.nimh.nih.gov.
 
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

ninds-10_l.jpg

Making “scents” of new cells in the brain’s odor-processing area
Adult-born cells travel through the thin rostral migratory stream before settling into the olfactory bulb, the large structure in the upper right of the image. Courtesy of the Belluscio Lab, NINDS.

Posted: 10/18/2014 4:20:10 PM by Don Margolis | with 0 comments


Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
Center for Adult Stem Cell Research and Regenerative Medicine
Our goal for the newly established Center for Adult Stem Cell Research and Regenerative Medicine is to shape and lead in the research, ethics, and societal implications for the field of adult.
 
Posted: 10/13/2014 4:33:42 PM by Don Margolis | with 0 comments


Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
A stroke therapy using stem cells extracted from patients’ bone marrow has shown promising results in the first trial of its kind in humans.
 
Five patients received the treatment in a pilot study conducted by doctors at Imperial College Healthcare NHS Trust and scientists at Imperial College London.
 
The therapy was found to be safe, and all the patients showed improvements in clinical measures of disability.
The findings are published in the journal Stem Cells Translational Medicine. It is the first UK human trial of a stem cell treatment for acute stroke to be published.
 
The therapy uses a type of cell called CD34+ cells, a set of stem cells in the bone marrow that give rise to blood cells and blood vessel lining cells. Previous research has shown that treatment using these cells can significantly improve recovery from stroke in animals. Rather than developing into brain cells themselves, the cells are thought to release chemicals that trigger the growth of new brain tissue and new blood vessels in the area damaged by stroke.


“Our aim is to develop a drug, based on the factors secreted by stem cells, that could be stored in the hospital pharmacy so that it is administered to the patient immediately following the diagnosis of stroke in the emergency room.”

– Professor Nagy Habib
Department of Surgery and Cancer

 
JbUaLkP.jpg
MRI scans showing brain damage in the stroke patients before treatment. Source: Stem Cells Translational Medicine.

The patients were treated within seven days of a severe stroke, in contrast to several other stem cell trials, most of which have treated patients after six months or later. The Imperial researchers believe early treatment may improve the chances of a better recovery.
 
A bone marrow sample was taken from each patient. The CD34+ cells were isolated from the sample and then infused into an artery that supplies the brain. No previous trial has selectively used CD34+ cells, so early after the stroke, until now.
 
Although the trial was mainly designed to assess the safety and tolerability of the treatment, the patients all showed improvements in their condition in clinical tests over a six-month follow-up period.
 
Four out of five patients had the most severe type of stroke: only four per cent of people who experience this kind of stroke are expected to be alive and independent six months later. In the trial, all four of these patients were alive and three were independent after six months.
 
Dr Soma Banerjee, a lead author and Consultant in Stroke Medicine at Imperial College Healthcare NHS Trust, said: “This study showed that the treatment appears to be safe and that it’s feasible to treat patients early when they might be more likely to benefit. The improvements we saw in these patients are very encouraging, but it’s too early to draw definitive conclusions about the effectiveness of the therapy. We need to do more tests to work out the best dose and timescale for treatment before starting larger trials.”
 
Over 150,000 people have a stroke in England every year. Survivors can be affected by a wide range of mental and physical symptoms, and many never recover their independence.
 
Stem cell therapy is seen as an exciting new potential avenue of treatment for stroke, but its exact role is yet to be clearly defined.
 
Dr Paul Bentley, also a lead author of the study, from the Department of Medicine at Imperial College London, said: “This is the first trial to isolate stem cells from human bone marrow and inject them directly into the damaged brain area using keyhole techniques. Our group are currently looking at new brain scanning techniques to monitor the effects of cells once they have been injected.”
 
Professor Nagy Habib, Principal Investigator of the study, from theDepartment of Surgery and Cancer at Imperial College London, said: “These are early but exciting data worth pursuing. Scientific evidence from our lab further supports the clinical findings and our aim is to develop a drug, based on the factors secreted by stem cells, that could be stored in the hospital pharmacy so that it is administered to the patient immediately following the diagnosis of stroke in the emergency room. This may diminish the minimum time to therapy and therefore optimise outcome. Now the hard work starts to raise funds for this exciting research.”
 
The study was funded by OmniCyte Ltd and the National Institute for Health Research Imperial Biomedical Research Centre.

Posted: 10/10/2014 4:25:28 PM by Don Margolis | with 0 comments


Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
After more than 20 years of research, a team of scientists are bioengineering penises in the lab which may soon be transplanted safely on to patients. It is an extraordinary medical endeavour that has implications for a wide range of disorders.

regeneration-penis-atala-011.jpg

Dr Anthony Atala: ‘We were completely stuck. We had no idea how to make this structure, let alone make it so it would perform like the natural organ.’

Gathered around an enclosure at the Wake Forest Institute for Regenerative Medicine in North Carolina in 2008, Anthony Atala and his colleagues watched anxiously to see if two rabbits would have sex. The suspense was short-lived: within a minute of being put together, the male mounted the female and successfully mated.
 
While it’s not clear what the rabbits made of the moment, for Atala it was definitely special. It was proof that a concept he’d been working on since 1992 – that penises could be grown in a laboratory and transplanted to humans – was theoretically possible. The male rabbit was one of 12 for which he had bioengineered a penis; all tried to mate; in eight there was proof of ejaculation; four went on to produce offspring.

The media’s coverage of Atala’s announcement a year later was understandably excited. Not just because of the novelty of a man growing penises in a laboratory, but because his work would fulfil a real need for men who have lost their penis through genital defects, traumatic injury, surgery for aggressive penile cancer, or even jilted lovers exacting revenge.
 
At present, the only treatment option for these men is to have a penis constructed with skin and muscle from their thigh or forearm. Sexual function can be restored with a penile prosthetic placed inside. The prosthetics can be either malleable rods, with the penis left in a permanently semi-rigid state and thus difficult to conceal, or inflatable rods, which have a saline pump housed in the scrotum. Both technologies have been around since the 1970s. The aesthetics are crude and penetration is awkward.
 
Another option is a penis transplant from another individual, but this carries a risk of immunological rejection. The chance of organ death can be lessened with anti-rejection drugs, but these drugs have serious side-effects. Transplants can also have a psychological impact, especially with an organ as intimate as the penis. In 2006, a Chinese man was the first to receive a donor penis; two weeks after the 15-hour operation, surgeons removed the transplanted organ on the request of both the patient and his partner.

Atala hopes his technique will mitigate both immunological and psychological issues because his penises would be engineered using a patient’s own cells. “The phallus is actually much longer than you think,” he explains. “It goes all the way behind the pelvis, so no matter the extent of the damage, there is a high probability that there are salvageable cells.”
 
Peruvian-born Atala, a urological surgeon and professor of regenerative medicine, heads a 300-strong team at the institute. He corrects himself constantly, always going back to edit his speech, adding words such as “high probability“ or “in all likelihood” to be sure his sentences are word-perfect. Soft-spoken and mild-mannered, Atala is a trailblazer in the field and you can’t help but think that his measured speech is an attempt to provide a sure path for others to follow.
 
To some, engineering human organs sounds like science fiction, but for Atala it’s an absolute necessity. As we live longer (and thus our organs fail more) the shortage of organs for donation will only get worse. If he can work out how to generate the organs people need in a reliable and effective way, the technology can improve a lot of people’s lives. In 2006, Atala and his team announced the first successful bioengineered organ transplant, a bladder, which had been implanted into seven patients in 1999. Earlier this year he announced the successful follow-up of four women given bioengineered vaginas in 2005-2008. Despite these successes, he says, the penis is proving trickier.
 
Organs increase in architectural complexity as they go from flat structures such as skin, cylindrical structures such as the vagina, to hollow non-tubular organs such as the bladder. As a solid organ, the penis tops this list in both density of cells and structural complexity. It consists of a spongy erectile tissue unique to it. During an erection, signals from the nerves trigger blood vessels to dilate, filling this spongy tissue with blood and causing the penis to lengthen and stiffen.
 
“We were completely stuck,” says Atala of the first few years of research in the early 90s. “Even the idea of the field of regenerative medicine was brand new at the time. We had no idea how to make this structure, let alone make it so it would perform like the natural organ.” Then, in 1994, he figured he could take a helping hand from Mother Nature. Using a technique pioneered for biological skin dressings, he would take a donor penis and soak it in a mild detergent of enzymes for a couple of weeks to wash away the donor cells.
 
“You’re left with a mostly collagen scaffold – a skeleton if you like, that looks and feels just like the organ,” explains James Yoo, one of Atala’s collaborators at the institute. “Think of it like a building. If you remove all the furniture and the people, you’re still left with the main structure of the building. Then you replace the tenants with new ones. That’s the whole idea. It’s just that the building is a penis and the tenants are cells.”
 
The next step is to reseed the structure with the patient’s own cells taken in a biopsy from salvageable tissue and grown in culture. Smooth muscle cells, which relax during an erection to allow the vessels to dilate and the penis to fill with blood, are first, followed by endothelial cells which line the interior surface of blood and lymphatic vessels. When ready, the bioengineered penis is ready to be transplanted to the recipient.
 
So why, six years on from successfully engineering a penis for rabbits, have they not yet done the same for humans? Atala explains that, as is often the case with these things, scaling up is proving difficult. “Even though we can make them in a very small mammal, we have to tweak the technology, the processes, the ratio of cells and so on, to get larger and larger structures. That’s pretty much what we’ve been doing since the rabbits.”
 
They’ve made encouraging progress. Atala has engineered half a dozen human penises. Although they are not yet ready for transplanting, Atala’s team are assessing the structures for safety and effectiveness. One machine squashes, stretches and twists them to make sure they can stand up to the wear of everyday life; another pumps fluid into them to test erections. Sliced segments are tested at the genetic, cellular and physiological level.
 
“It’s a rigorous testing schedule,” says Atala, wearily. “But we’re trying to get approval from the US Food and Drug Administration so we know everything is perfect before we move to a first in-man test.”
 
Neither Atala nor Yoo will be pushed for a date for the first test in man, saying only that they’d expect it to occur within five years. “In the end we’re aiming for the entire size of the organ,” says Atala. “But in reality our first target is going to be partial replacement of the organ.”
 
In the short term, this would include growing smaller lengths for partially damaged penises, but would also include replacing parts of the penis to help cure erectile dysfunction. Degradation of the spongy erectile tissue, says Tom Lue, a urological surgeon at the University of California, San Francisco, is the leading cause of impotence in old age. Disorders such as high blood pressure or diabetes can damage the delicate tissue – the resulting scar tissue is less elastic, meaning the tissue cannot completely fill with blood and the penis cannot become fully erect.
 
“Show me a hundred 70-year-old men with erectile dysfunction,” says Lue, “and I’ll bet you 90% of them have scar material in their penis.” Traumatic injury or priapism, a condition that leaves men with an increasingly painful erection for hours or even days, can also damage the tissue and cause erectile dysfunction in younger men. “If you replace the damaged spongy tissue you can give these men a better erection.”
 
Engineering the spongy tissue for replacement is one of Atala and Yoo’s interim goals. Lue is also hoping to restore erections, but for less severely damaged penises. For instance, some men become impotent after surgery for prostate or rectal cancer because the nerves that regulate erections, which run through the rectum and prostate into the centre of the penis, can get damaged. Likewise with traumatic injury, if the vessels are severed then the penis cannot fill with blood.
 
Microsurgery to connect the vessels and nerves in the penis is possible but often ineffective. Lue is testing whether injecting stem cells into the base of the penis can encourage the nerves and cells to rejoin. His work might also help Atala and Yoo to stimulate nerve and vessel regrowth when the day comes for the first in-man trial of a bioengineered penis. Twenty-two years into his research to bioengineer a human penis, Atala is a man who is both excited and impatient for that day. And you’d suspect he’s not the only one.

Bioengineered organs: The story so far…

Bladder
 
In 1999 the bladder became the first laboratory-grown organ to be given to a human. Atala and his colleagues took cells from a biopsy from seven patients with bladder disease. The cells were cultured and then seeded, layer by layer, on to a biodegradable, bladder-shaped collagen scaffold. After about eight weeks they were transplanted to patients, where the organs developed and integrated into the body.
 
Vagina
 
Another pilot study, this time in four women with a rare congenital abnormality that causes the vagina and uterus to be underdeveloped or absent. Using a similar technique to the one used to make bladders, in 2005 they implanted the first vagina. Up to eight years after transplant, all four organs have normal structure and function. This technique could be used to help women following injury or cancer.
 
Penis and beyond
 
In 2004, they implanted the first bioengineered urethra into five boys. This technology will help in their work towards reconstructing the penis. Atala and his colleagues are also working on 30 different organs and tissues including a kidney, which could be made using a 3D printer, and tissue for the liver, heart and lung.

Posted: 10/8/2014 11:09:10 AM by Don Margolis | with 0 comments


Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
Israel's BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration has designated its adult stem cell treatment as a "fast-track" product for the treatment of amyotrophic lateral sclerosis (ALS).

BrainStorm's treatment, called NurOwn, is being studied in a mid-stage clinical trial in patients with ALS, also known as Lou Gehrig's Disease.
 
The FDA's fast track program is designed to speed up access to drugs intended to treat serious conditions and which have the potential to address unmet medical needs.
 
"The receipt of fast-track designation from the FDA is an acknowledgement of the unmet medical need in ALS," BrainStorm Chief Executive Tony Fiorino said on Tuesday.
 
"What is so valuable about fast track designation to a small company like BrainStorm is the opportunity to have increased meetings with and more frequent written communication from the FDA," he said, adding that only a small number of cellular therapies have received FDA approval.
 
BrainStorm said the last patient has completed the last visit in its phase 2a clinical trial in ALS at Hadassah Medical Center in Jerusalem. The company expects to release final results of the study in the fourth quarter of 2014.
 
NurOwn is also being studied in a phase 2 clinical trial at three sites in the United States.
 
According to the ALS Association, 5,600 people in the United States are diagnosed each year with the disease, which has severely disabled British physicist Stephen Hawking.
Posted: 10/7/2014 11:06:00 AM by Don Margolis | with 0 comments


Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
Ryan Benton, a 28 year-old Duchenne’s muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday following US FDA approval of his doctor’s application for a single patient, investigational new drug (IND) for compassionate use.

After FDA Approval, Duchenne’s Muscular Dystrophy Patient Receives First Umbilical Cord Stem Cell Treatment in the United States

Ryan Benton, a 28 year-old Duchenne’s muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday at Asthma and Allergy Specialists of Wichita, KS following US FDA approval of his doctor’s application for a single patient, investigational new drug (IND) for compassionate use.


Picture of Ryan Benton

Ryan Benton

Wichita, KS (PRWEB) September 10, 2014

Ryan Benton, a 28 year-old Duchenne’s muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday following US FDA approval of his doctor’s application for a single patient, investigational new drug (IND) for compassionate use.

Duchenne muscular dystrophy (DMD) is a rapidly progressive form of muscular dystrophy that occurs primarily in boys. It is caused by an alteration (mutation) in a gene, called the DMD gene, which causes the muscles to stop producing the protein dystrophin. Individuals who have DMD experience progressive loss of muscle function and weakness, which begins in the lower limbs and leads to progressively worsening disability. Death usually occurs by age 25, typically from lung disorders. There is no known cure for DMD.

This trial, officially entitled “Allogeneic transplantation of human umbilical cord mesenchymal stem cells (UC-MSC) for a single male patient with Duchenne Muscular Dystrophy (DMD)” marks the first time the FDA has approved an investigational allogeneic stem cell treatment for Duchenne’s in the United States.

Ryan received his first intramuscular stem cell injections from allergy and immunology specialist, Van Strickland, M.D at Asthma and Allergy Specialists in Wichita, Kansas. He will receive 3 more treatments this week on consecutive days. Dr. Strickland will administer similar courses to Ryan every 6 months for a total of 3 years.

This is not the first time Ryan has undergone umbilical cord mesenchymal stem cell therapy. Since 2009, Ryan has been traveling to the Stem Cell Institute in Panama for similar treatments. Encouraging results from these treatments prompted Dr. Strickland to seek out a way to treat Ryan in the United States.via

Am I a Candidate for Stem Cell Treatment for Duchenne Muscular Dystrophy?
 

Posted: 9/22/2014 12:00:00 AM by CJ Simpson | with 0 comments


Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
Newswise Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.
 
The trial will assess the safety and efficacy of a new investigational drug called VC-01, which was recently approved for testing by the U.S. Food and Drug Administration. The 2-year trial will involve four to six testing sites, the first being at UC San Diego, and will recruit approximately 40 study participants.
 
The goal, first and foremost, of this unprecedented human trial is to evaluate the safety, tolerability and efficacy of various doses of VC-01 among patients with type 1 diabetes mellitus, said principal investigator Robert R. Henry, MD, professor of medicine in the Division of Endocrinology and Metabolism at UC San Diego and chief of the Section of Endocrinology, Metabolism & Diabetes at the Veterans Affairs San Diego Healthcare System. We will be implanting specially encapsulated stem cell-derived cells under the skin of patients where its believed they will mature into pancreatic beta cells able to produce a continuous supply of needed insulin. Previous tests in animals showed promising results. We now need to determine that this approach is safe in people.
 
Development and testing of VC-01 is funded, in part, by the California Institute for Regenerative Medicine, the states stem cell agency, the UC San Diego Sanford Stem Cell Clinical Center and JDRF, the leading research and advocacy organization funding type 1 diabetes research.
 
Type 1 diabetes mellitus is a life-threatening chronic condition in which the pancreas produces little or no insulin, a hormone needed to allow glucose to enter cells to produce energy. It is typically diagnosed during childhood or adolescence, though it can also begin in adults. Though far less common than Type 2 diabetes, which occurs when the body becomes resistant to insulin, Type 1 may affect up to 3 million Americans, according to the JDRF. Among Americans age 20 and younger, prevalence rose 23 percent between 2000 and 2009 and continues to rise. Currently, there is no cure. Standard treatment involves daily injections of insulin and rigorous management of diet and lifestyle.

Phase I/II clinical trials are designed to assess basic safety and efficacy of therapies never before tested in humans, uncovering unforeseen risks or complications. Unpredictable outcomes are possible. Such testing is essential to ensure that the new therapy is developed responsibly with appropriate management of risks that all medical treatments may present.
 
This is not yet a cure for diabetes, said Henry. The hope, nonetheless, is that this approach will ultimately transform the way individuals with Type 1 diabetes manage their disease by providing an alternative source of insulin-producing cells, potentially freeing them from daily insulin injections or external pumps.
 
This clinical trial at UC San Diego Health System was launched and supported by the UC San Diego Sanford Stem Cell Clinical Center. The Center was recently created to advance leading-edge stem cell medicine and science, protect and counsel patients, and accelerate innovative stem cell research into patient diagnostics and therapy.
 
Link:

Posted: 9/20/2014 5:28:18 AM by Don Margolis | with 0 comments


Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
Hong Kong LEmed, the specialist stem cell and laser therapy research and distribution group, announced today that it is supporting ALS research which uses Adult Stem Cells, the only stems cells to successfully complete clinical trials for incurable diseases.
 
Wan Chai, Hong Kong, September 15, 2014 -- Hong Kong LEmed (Leading Edge Medical Ltd.), the specialist stem cell and laser therapy research and distribution group, announced today that it is supporting ALS research which uses Adult Stem Cells, the only stems cells to successfully complete clinical trials for incurable diseases.
 
In view of the enormous amount of attention the ice bucket challenge has brought to ALS (Amyotrophic Lateral Sclerosis) often referred to as Lou Gehrig's Disease, LEmed is excited to be at the forefront of the revolutionary stem cell treatment technology used to fight this horrific disease.

Considering the fact that no effective long-term treatment exists for patients with ALS as well as a long list of neuro-inflammatory and neuro-degenerative disorders, LEmed has encouraged one of its lead doctors, Professor Shimon Slavin of Tel Aviv, to press forward with his adult stem cell technology.
 
Dr. Slavin is one of the only stem cell MD's in the world who has been successfully treating no-hope patients with a large variety of life threatening malignant and non-malignant indications for more than 20 years. The current research efforts in Tel Aviv is directed towards developing new approaches for regenerative medicine focusing on the use of multi-potent mesenchymal stromal cells (MSC) derived from either bone marrow or fat tissue (the patient own cells), or using unrelated placenta & cord tissue MSCs, derived from healthy newborn babies.
 
He has documented how, using new innovative technologies, that MSCs from all sources can be targeted to any part of the central nervous system by a non-invasive extra corporeal technology based on the use of low energy acoustic shockwave therapy. In parallel, they attempt to activate undifferentiated MSCs by multi-channel low energy laser light therapy, all of which are theoretically potentially beneficial to ALS patients and most likely to other indications of neuro-inflammatory and neuro-degenerative disorders.
 
The future goal is to use differentiated MSCs, both autologous and readily available allogeneic off-the-shelf, using differentiated placenta & cord tissue derived MSCs that were also shown to secrete neurotrophic factors that may help regulate the function of neurons in the brain and also play an important role in repairing or replacing damaged neurons. Such factors may also be therapeutically effective by activation of locally residing multi-potent stem cells located throughout the central nervous system, which otherwise do not respond to the body need.


LEmed strongly recommends supporting these research efforts that are the most promising by an experienced team that has already treated several hundreds of patients with ALS and a variety of other neuro-degenerative disorders and autoimmune diseases, thus far with undifferentiated MSCs. Clinical application of the next generation of cellular therapy depends on additional research to confirm the advantage of targeted, activated and also differentiated MSCs in comparison with current therapeutic approach based on the use of undifferentiated MSCs enriched in vitro.  Considering the genetic background of patients with familial type ALS and more subtle molecular abnormalities even in patients considered as sporadic ALS, and the practical need to have available readily available cells for treatment of patients with rapidly progressive disease, much attention will be given in the future to the use of young and normal MSCs derived from placenta & cord tissue of normal newborn babies of consenting mothers
 
Donations should be addressed to CordCure Ltd in Tel Aviv, Israel, earmarked for ALS Research.
 
Account Name: CordCure
Bank Poalim  Main Branch # 170 50 Rothchild Street Tel Aviv 61000
 
Account # 170-223405 Swift: POALILIT IBAN: IL880121700000000223405
 
About Leading Edge Medical Ltd.:
Cellular medicine is revolutionizing medical treatment in the 21st century and Leading Edge Medical's treatments are at the forefront of the field. Thousands of patients around the world have already benefited from bio-technologies using stem cells and intravenous laser therapy. Diseases once considered incurable are responding well to stem cell therapies and are restoring a quality of life to patients they thought they had lost forever.
 
LEmed is committed to applying modern day best practices to the growing field of regenerative medicine. With advanced medical treatment facilities offering personalized, ongoing care plans and the highest quality of customer service, we are dedicated to providing a better life for patients.


Contact:
Jeffery Tobin
Leading Edge Medical, Ltd
14F, 8 Hennessy Road
China Hong Kong Tower
Wan Chai, Hong Kong 999077
+852 21270684
info@healingmed.com
http://www.healingmed.com
Posted: 9/17/2014 4:02:15 PM by Don Margolis | with 0 comments


Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
Millions of Americans took the challenge. They doused themselves with ice water and sent a check to the ALS Association to help fund the fight against the almost always deadly disease. Now, there is hope for a treatment, coming out of Isreal.
 
The treatment is called NurOwn, and it was developed by the Isreali biotechnology company BrainStorm Cell Therapeutics. The treatment harvests a patient’s stem cells from their bone marrow, treats the cells with chemicals until they grow new neurons, then injects them into that patient’s spinal fluid. Researchers hoped NurOwn would slow the progression of ALS, and it appears to have done that in several Isreali patients.
 
That success in Isreal has led to Phase II clinical trials at three locations in the United States. Those in the American ALS community — like Tanner Hockensmith, with the Texas Chapter of the ALS Association — are watching these trials closely.

“It’s an exciting, new, scientific breakthrough that we haven’t really seen, and there have been a lot of advances about how to come up with stem cells, looking past embryonic stem cells, going to adult stem cells and regrowing them for trials and treatments, so there are still a lot of exciting things happening.”

Hockensmith says any time there are American trials of an ALS treatment, it’s another shot on goal for those struggling against the disease, and he says, “The more shots we can get on goal, as far as attempts at trials like this, is the best, in the long run, for ALS patients.”
 
Perhaps as exciting as NurOwn’s potential as a treatment for ALS patients is its potential for treating many other diseases. Hockensmith says, “If this gets traction, it isn’t just good news for ALS patients. There are things in this that could possibly help other neurologic diseases, as well, so it’s a win-win for everybody when things like this get approved.”
 
So NurOwn may offer hope to people with diseases like Parkinson’s and Multiple Sclerosis.
The U.S. trials of NurOwn start this fall, and will end in 2016.

Posted: 9/15/2014 4:36:11 PM by Don Margolis | with 0 comments


Displaying results 21-30 (of 715)
 |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >| 

Treatment Information

CLICK HERE

To request information on NOW AVAILABLE stem cell treatments for the MEDICAL CONDITION you are interested in.

Newsletter Sign Up

CLICK HERE

To request the RSCI Newsletter on stem cell treatments and information.

Who is Don Margolis

CLICK HERE

To learn more about RSCI's founder Don Margolis

Tag Cloud

AdiCyte Adipose adult allogeneic ALS Alzheimer Alzheimer's Amyotrophic Lateral Sclerosis Anemia Anti-Aging Arteries Artery Arthritis Asperger Asthma Ataxia Autism Autoimmune autologous Batten Disease biology Blood BONE Bone Fractures BRAIN Bronchiectasis Bypass CANCER Cancers cardiac cardiovascular cartilage cell Cells cerebral Cerebral Palsy chronic Chronic Inflammatory Demyelinating Polyneuropathy Chronic Obstructive Pulmonary Disease Cirrhosis Congestive Congestive Heart Failure COPD cord Coronary Cosmetic cp Crohn's cure Dementia diabetes Diabetes Type 1 Diabetes Type 2 Diabetic Diabetic Foot Donation Dr.Johnson Duchenne Duchenne Muscular Dystrophy Dystrophy embryonic Emphysema Epilepsy evolution Exercise Facial Rejuvenation Failure fox Gastro Gehrig Gilbert Glucose Glycemic Graft Grow heal Heart hypertension Infantile Spasms Intestinal j Jewish K Kidney Leukemia Liposuction Liver Longevity Lou Gehrig Lung Lupus Lymphoma Marrow MDS Meningitis Mesems Mesenchymal Mesoblast michael Motor Neuron MPC MS Multiple Multiple Myeloma Multiple Sclerosis Muscular Muscular Dystrophy Myeloma Neuropathy Olivopontocerebellar Atrophy oprah optic Optic Nerve Optic Nerve Damage Optic Nerve Hypoplasia Osteoarthritis Osteonecrosis oz palsy Parkinson Patent Peripheral Artery Disease Peripheral Vascular Disease Precursor Pulmonary Fibrosis Pulmonary Hypertension reconstruct Regenerate Regeneration Renal Renal Failure Repair research Rheumatoid Arthritis Schumer sci science Sclerosis Septo-Optic Dysplasia Spasm Spectrum Disorder Spina Bifida Spinal Cord Spinal Muscular Atrophy stem Stem Cells Stemmys Stroke Study SVF TBI Teat Technology Tendonitis Thalassemia therapy Tissue Transplant treat Treatment Trial umbilical Vascular Diseases Vatican Ventricular Vessel
Bookmark this page to:Add to Twitter Add to Newsvine Add to MySpace Add to Link-a-Gogo Add to Multiply Add to MyAOL Add to Diigo Add to Yahoo Bookmarks Add to Yahoo MyWeb Add to Facebook Add to Mister Wong Add to Terchnorati Add to Segnalo Add to Digg Add to Google Bookmarks Add to Reddit Add to Faves Add to Blogmarks Add to StumbleUpon Add to Delicious